Newsmeme!
Discover News you didn't know existed
ATTENTION EDITORS,
Use of the drug interferon as a long-term maintenance strategy to slow the progression of liver disease associated with the hepatitis C virus is ineffective, UT Southwestern Medical Center researchers and their colleagues from nine other institutions have found in a multicenter study.
MONTREAL, QUEBEC-- - Ambrilia Biopharma Inc. announced today that it has entered into an exclusive license option agreement with ZBx Corporation granting ZBx the worldwide rights to develop, manufacture and commercialize Ambrilia's PSP94 technology in ZBx's Zap Rapid Test Systems and Assays.
NEOSTEM PLACEMENT... NEW YORK - NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medi
Tibotec Pharmaceuticals announced today that the European Commission adopted the decision to broaden the indication for PREZISTA® (darunavir), a protease inhibitor, in combination with ritonavir and other antiretroviral medicinal products to the treatment of HIV-1 infection in all treatment-experienced adult patients. Darunavir was developed by Tibotec Pharmaceuticals, Cork, Ireland.
On 1 January 2009 the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) will launch ten new Collaborative Research Centres. They will be initially funded for the next four years with a total of approximately 90 million euros.
Catalyst Biosciences Inc., which focuses on engineered proteases, said Wednesday it raised $40.4 million in a third round of funding.
Tibotec Pharmaceuticals today announced that it has signed a royalty-free, non-exclusive license agreement with Emcure Pharmaceuticals Limited of India to distribute the protease inhibitor darunavir in India.
Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase therapeutics, has raised $40.4 million in a Series C financing round.
Cork, Ireland (ots/PRNewswire) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment-Experienced Patients in the 27 EU ...
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |